글로벌 조혈모세포 이식 시장 – 2030년까지의 산업 동향 및 예측

조혈모세포 이식 시장 분석 및 규모

최근 몇 년 동안 조혈모세포 이식 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. GLOBOCAN 2018 연구에 따르면 2018년 전 세계 백혈병 발병률은 437,033건의 신규 발병과 약 309,006건의 사망으로 예상되었습니다. 세계보건기구(WHO)에 따르면 매년 2,000건 이상의 제대혈 조혈모세포 이식이 시행됩니다. 골수와 혈액에는 조혈모세포(HSC)가 포함되어 있습니다. 조혈모세포는 조혈모세포(HPC)의 다른 이름입니다. 조혈모세포는 혈소판, 백혈구, 적혈구 등을 생성할 수 있습니다. 이러한 세포는 악성(림프종 및 백혈병 등) 및 비악성(골수 기능 부전 및 혈색소병 포함) 장애를 치료하는 데 환자의 조혈계를 재건하거나 대체하는 데 사용됩니다.

Data Bridge Market Research는 2022년에 2,610.91백만 달러였던 글로벌 조혈모세포 이식 시장이 2030년까지 6,327.28백만 달러로 급증할 것이며 예측 기간 동안 11.7%의 CAGR을 기록할 것으로 분석했습니다. 이는 시장 가치를 나타냅니다. "(자가 HSCT)"는 더 나은 진단 및 치료 방법에 대한 수요가 증가함에 따라 글로벌 조혈모세포 이식 시장의 유형 세그먼트를 지배하고 있습니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

조혈모세포 이식 시장 범위 및 세분화

시장 정의

조혈모세포 이식(HSCT)은 다양한 암 유형과 기타 질병에 대한 치료 옵션입니다. 혈액 줄기 세포와 골수 줄기 세포는 모두 줄기 세포의 공급원입니다. 골수에 존재하는 젊거나 미성숙한 혈액 세포를 조혈모세포라고 합니다. 이러한 혈액 세포 중 소수만이 골수에서 성숙하여 혈류로 들어갑니다. 말초 혈액 줄기 세포는 혈류로 들어가는 세포입니다. 조혈모세포 이식은 화학 요법이나 방사선 치료의 결과로 없어지거나, 아프거나, 손상된 조혈모세포를 건강한 조혈모세포로 대체합니다.

글로벌 조혈모세포 이식 시장 동향

운전자

• 백혈병과 림프종의 유병률 증가

백혈병과 림프종의 유병률 증가는 조혈모세포 이식 시장의 성장을 촉진할 것으로 추정됩니다. 백혈병 및 림프종 학회의 2019년 보고서에 따르면 미국에서 176,200명이 백혈병, 림프종 또는 골수종 진단을 받았고 1,399,180명이 림프 백혈병과 골수종을 앓고 있었습니다. 발병률이 증가함에 따라 조혈모세포 이식(HSCT)에 대한 수요가 증가하여 HSCT 시장이 발전할 가능성이 높습니다.

• 노령 인구의 증가

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to getting hematopoietic stem cell transplantation, further estimated to enhance the market's growth rate

Opportunities

• Advancements in Transplantation Techniques

The field of HSCT continues to evolve, with advancements in transplantation techniques, supportive care, and donor selection strategies. These advancements have improved transplant outcomes, expanded eligibility criteria, and increased the number of patients who can benefit from HSCT. The market can capitalize on these advancements to offer innovative transplantation solutions and expand the patient pool.

• Increasing Adoption of Autologous HSCT

Autologous HSCT involves using a patient's stem cells, often collected and stored prior to high-dose chemotherapy or radiation therapy. The demand for autologous HSCT is increasing due to its potential benefits, such as reduced risk of GVHD and improved survival rates. This trend presents an opportunity for market players to expand their offerings and develop innovative solutions specifically tailored to autologous HSCT

• Growing Medical Tourism

Medical tourism, where patients travel to other countries for medical treatments, including HSCT, is on the rise. Factors such as cost advantages, availability of specialized centers, and shorter waiting times in certain regions attract patients seeking HSCT. This presents an opportunity for market players to cater to international patients and collaborate with medical tourism facilitators.

Restraints/Challenges

• Limited Availability of Suitable Donors

HSCT requires a suitable donor match for successful transplantation. However, finding a suitable donor, especially for allogeneic transplantation, can be challenging due to the need for human leukocyte antigen (HLA) compatibility. The limited availability of suitable donors can restrict the number of patients who can undergo HSCT.

• Transplant-Related Morbidity and Mortality

HSCT carries a risk of complications, including graft failure, graft-versus-host disease (GVHD), infections, organ toxicity, and relapse. These complications can lead to significant morbidity and even mortality. The risk of these adverse events can deter both patients and healthcare providers from considering HSCT as a treatment option, particularly for older or medically fragile patients.

• Lack of Standardization

HSCT involves a complex process with various steps and components, including stem cell collection, conditioning regimens, and post-transplant care. The lack of standardization in protocols, procedures, and supportive care practices can lead to variability in outcomes and hinder the widespread adoption of HSCT.

• Long-Term Follow-up and Survivorship Care

HSCT survivors require long-term follow-up care, including monitoring for late effects, managing chronic graft-versus-host disease (GVHD), and addressing psychosocial and quality-of-life issues. The provision of comprehensive survivorship care can be challenging due to limited resources, coordination of multidisciplinary care, and addressing the unique needs of HSCT survivors.

This hematopoietic stem cell transplantation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hematopoietic stem cell transplantation market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth

Recent Developments

• In August 2021, Magenta Biosciences, announced a spin-off collaboration with bluebird bio to develop HSPC-based gene therapies for genetic diseases. The specific date of this announcement is not provided.
• In July 2020, Gamida Cell announced positive results from a Phase 3 clinical trial of NiCord, an investigational product. The trial showed improved overall survival and reduced time to neutrophil engraftment compared to standard umbilical cord blood transplantation.

This global hematopoietic stem cell transplantation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hematopoietic stem cell transplantation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hematopoietic Stem Cell Transplantation Market Scope

The global hematopoietic stem cell transplantation market is categorized into five notable segments, which are based on the basis of product, sample, mode of purchase, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Allogeneic HSCT
• Autologous HSCT
• Others

 Indication

• Congenital Metabolic Defects
• Hemoglobinopathies
• Myelodysplastic Syndrome
• Myeloproliferative Syndromes
• Multiple Sclerosis
• Lymphoma
• Immune-Deficiency Illnesses
• Others

Application

• Bone Marrow Stem Cells
• Peripheral Blood Stem Cells
• Umbilical Cord Stem Cells
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Hematopoietic Stem Cell Transplantation Market Regional Analysis/Insights

The global hematopoietic stem cell transplantation market is analysed and market size insights and trends are provided by country, type, indication, application, end-users and distribution channel as referenced above.

The countries covered in the hematopoietic stem cell transplantation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.

North America dominates the hematopoietic stem cell transplantation market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of patients.

Asia-Pacific is expected to witness significant growth during the forecast period from 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for skin care, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

경쟁 환경 및 글로벌 조혈모세포 이식 시장 점유율 분석

글로벌 조혈모세포 이식 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭 및 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 글로벌 조혈모세포 이식 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 조혈모세포 이식 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 오츠카 아메리카 제약 주식회사(미국)
• 아카리 테라퓨틱스 주식회사(미국)
• 머크 KGaA(독일)
• 다케다제약 주식회사(일본)
• 론자(스위스)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• 머크앤코(미국)
• 파이저 주식회사(미국)
• 사노피(프랑스)
• 후지필름 홀딩스 주식회사(일본)
• 블루버드 바이오 주식회사(미국)
• Pluristem Therapeutics Inc. (이스라엘)
• Regen Biopharma Inc. (미국)
• Kiadis Pharma(네덜란드)
• Taiga Biotechnologies, Inc. (미국)
• CellGenix GmbH(독일)
• Escape Therapeutics, Inc. (미국)
• Marker Therapeutics, Inc. (미국)
• 탈라리스 테라퓨틱스(미국)

SKU-53864